

NOUVEAU LIFE PHARMACEUTICALS, INC.

ANNUAL DISCLOSURE STATEMENT

December 31, 2014

Trading Symbol
NOUV

1) Name of the issuer and its predecessors (if any)

Nouveau Life Pharmaceuticals, Inc.

- Formerly known as Hybrid Fuel, Inc. until 5-2012 and Polo Equities, Inc. until 6-1998.

2) Address of the issuer's principal executive offices

Mailing Address:

Nouveau Life Pharmaceuticals, Inc.

401 E. Las Olas Blvd

Ft. Lauderdale, Florida 33301

IR Contact

None

3) Security Information

Trading Symbol:

NOUV

Exact title and class of securities outstanding:

Common

CUSIP: 66979K 103

Par or Stated Value: \$0.0001

Common shares authorized: ----- 2,000,000,000

Total shares outstanding ----- 1,989,999,733

Preferred

Preferred shares authorized: ----- 10,000,000

Preferred shares outstanding: ----- 10,000,000

Transfer Agent

Pacific Stock Transfer Company

173-3 Keith Street

Warrenton, VA 20186

Phone: (571) 485-9999

Is the Transfer Agent registered under the Exchange Act? Yes

List any restrictions on the transfer of security: None

Describe any trading suspension orders issued by the SEC in the past 12 months. List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

As of December 31, 2014, there were no trading suspensions, stock splits, dividends, recapitalizations, etc.

4) Issuance History Control shares (10% or more)

A. The nature of each offering (e.g., Securities Act Rule 504, intrastate, etc.);
The shares issued by the Company were issued in accordance with the Securities & Exchange Act section 4(2).

None

B. Any jurisdictions where the offering was registered or qualified;

N/A

C. The number of shares offered;

N/A

D. The number of shares sold;

N/A

E. The price at which the shares were offered,

N/A

F. The trading status of the shares;

Restricted

G. The certificates evidencing the shares contain a legend stating that the shares have not been registered under the Securities Act and set forth the restrictions on transferability and sale of the shares under the Securities Act. Officers, directors and control shares are restricted from sale and bear a legend setting forth the restrictions on transferability.

5) Financial Statements

The Company's unaudited financial statements are posted to the OTC Disclosure & News Service as a separate report. They were prepared in accordance with GAAP requirements by the Company's current CEO, Jeffrey Burns. Mr. Burns has sufficient knowledge to prepare the financials and has owned and operated his own businesses for over 15 years.

6) Describe the Issuer's Business, Products and Services

A. Date and State (or Jurisdiction) of Incorporation:

The issuer was incorporated in 1998 as a Nevada corporation.

B. The issuer's primary and secondary SIC Codes;

Primary SIC Code 2833 and 2836

C. The issuer's fiscal year end date;

December 31

D. Principal products or services, and their markets;

The business of the Company is to provide consumers with natural alternatives to prescription drugs for a new healthy life style. Nouveau Life will provide nutraceutical solutions to patients suffering from impotence, erectile dysfunction, acne, cholesterol and many other common conditions. The Company has already introduced its all natural male enhancement product known as Azul Instant to be distributed in the U.S. Hybrid Fuels' predecessor company originally incorporated in Florida on May 8, 1998 as Polo Equities. Polo Equities of Nevada changed the corporate domicile to Nevada. Polo Equities of Florida merged into Hybrid Fuels, Inc, which was a Nevada corporation; Hybrid Fuels, Inc. was the surviving entity.

7) Describe the Issuer's Facilities

The Company operates from its officer's place of residence. Due to the virtual nature of the business, there has been no requirement to obtain an office lease at this time.

8) Officers, Directors, and Control Persons

A. Names of Officers, Directors, and Control Persons.

On March 4, 2014 Llewellyn Watkins resigned and Gregory Chapman was appointed as CEO.

B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or

vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

None

C. Beneficial Shareholders of Greater than Five Percent (5%)

Mizata, Inc. - 47%

Yanci Rosales

PO Box P.O 2787

Merrifield, VA 22116

Warren Wheeler - 6%

102 Derbigny St.

Gretna, LA 70053

9) Third Party Providers

1. Investment Banker: None

2. Promoters: None

3. Legal Counsel: None

4. Accountants or Auditor: None - The company financial statements are currently prepared internally; they are not reviewed or audited.

5. Public Relations Consultant(s): None

6. Investor Relations Consultant: None

10) Issuer Certification

I, Jeffrey Burns certify that:

I have reviewed this annual disclosure statement of Nouveau Life Pharmaceuticals, Inc. and based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

January 24, 2017

/s/ Jeffrey Burns

CEO